Short Interest in Celularity Inc. (NASDAQ:CELU) Expands By 67.4%

Celularity Inc. (NASDAQ:CELU) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 287,400 shares, an increase of 67.4% from the January 31st total of 171,700 shares. Approximately 2.6% of the company’s stock are short sold. Based on an average daily volume of 167,600 shares, the short-interest ratio is presently 1.7 days.

Hedge Funds Weigh In On Celularity

Hedge funds have recently added to or reduced their stakes in the business. C V Starr & Co. Inc. acquired a new stake in Celularity during the fourth quarter worth about $1,589,000. Two Sigma Investments LP bought a new position in shares of Celularity during the fourth quarter valued at approximately $93,000. Biltmore Family Office LLC acquired a new stake in shares of Celularity during the 4th quarter worth approximately $73,000. Finally, Keynote Financial Services LLC lifted its holdings in shares of Celularity by 90.1% in the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock worth $52,000 after purchasing an additional 11,863 shares during the last quarter. Institutional investors and hedge funds own 19.02% of the company’s stock.

Celularity Stock Performance

NASDAQ CELU opened at $1.16 on Friday. The business has a 50 day moving average price of $2.09 and a two-hundred day moving average price of $2.42. Celularity has a fifty-two week low of $1.15 and a fifty-two week high of $7.97.

Celularity (NASDAQ:CELU) last released its quarterly earnings results on Friday, December 6th. The company reported ($0.73) EPS for the quarter. Celularity had a negative return on equity of 119.53% and a negative net margin of 72.72%.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.